Price, DavidHenley, WilliamDelfini Cançado, José EduardoFabbri, Leonardo MKerstjens, Huib AMPapi, AlbertoRoche, NicolasŞen, ElifSingh, DaveVogelmeier, ClausBarille, SaraNudo, ElenaCarter, VictoriaSkinner, DerekVella, RebeccaGeorges, George2022-02-162022-02-162022-02-15Price, D, Henley, W, Delfini Cançado, J E, Fabbri, L M, Kerstjens, H AM, Papi, A, Roche, N, Şen, E, Singh, D, Vogelmeier, C, Barille, S, Nudo, E, Carter, V, Skinner, D, Vella, R & Georges, G 2022, 'Interclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone', International journal of chronic obstructive pulmonary disease , vol. 2022, no. 17, pp. 355—370. https://doi.org/10.2147/COPD.S3423571176-9106https://hdl.handle.net/2164/18073Acknowledgements Professor Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Jaco Vooriham is acknowledged for his contribution to protocol development. We would also like to acknowledge Ms. Shilpa Suresh (MSc) of the Observational and Pragmatic Research Institute (OPRI), Singapore, for editorial and formatting assistance which supported the development of this publication.162542035engInhaled corticosteroidspneumoniaCOPDExtrafine beclometasonefluticasoneR MedicineSupplementary InformationRJournal article10.2147/COPD.S34235717